Angiosarcoma of liver
ICD-10 C22.3 is a billable code used to indicate a diagnosis of angiosarcoma of liver.
Angiosarcoma of the liver is a rare and aggressive form of cancer that originates from the endothelial cells lining the blood vessels of the liver. This malignancy is characterized by rapid growth and a tendency to metastasize early, often leading to a poor prognosis. Angiosarcoma can be associated with underlying liver conditions, particularly cirrhosis, which may predispose patients to the development of this cancer. The etiology of angiosarcoma can include exposure to certain chemicals, such as vinyl chloride and arsenic, as well as pre-existing liver diseases. Patients may present with symptoms such as abdominal pain, weight loss, and jaundice. Alpha-fetoprotein (AFP) levels can be elevated in some cases, although they are not specific to angiosarcoma and are more commonly associated with hepatocellular carcinoma. Treatment options may include surgical resection, liver transplantation, and chemotherapy, depending on the stage of the disease and the overall health of the liver. Given the aggressive nature of angiosarcoma, early diagnosis and intervention are critical for improving outcomes.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of liver tumors, including angiosarcoma.
Need for comprehensive documentation of tumor characteristics and treatment responses.
Liver function tests, history of liver disease, and imaging results.
Management of patients with cirrhosis and liver tumors.
Documentation of cirrhosis severity and its impact on treatment decisions.
Used when surgical intervention is required for angiosarcoma.
Operative reports detailing the extent of resection.
Oncology and hepatology must collaborate for optimal patient outcomes.
The prognosis for angiosarcoma of the liver is generally poor due to its aggressive nature and tendency to metastasize. Early detection and treatment are crucial for improving outcomes.
